作者
Jason M Pogue, Keith S Kaye, Michael P Veve, Twisha S Patel, Anthony T Gerlach, Susan L Davis, Laura A Puzniak, Tom M File, Shannon Olson, Sorabh Dhar, Robert A Bonomo, Federico Perez
发表日期
2020/7/11
期刊
Clinical Infectious Diseases
卷号
71
期号
2
页码范围
304-310
出版商
Oxford University Press
简介
Background
Ceftolozane/tazobactam is a novel cephalosporin/beta-lactamase inhibitor combination that often retains activity against resistant Pseudomonas aeruginosa. The comparative safety and efficacy vs polymyxins or aminoglycosides in this setting remains unknown.
Methods
A retrospective, multicenter, observational cohort study was performed. Patients who received ceftolozane/tazobactam were compared with those treated with either polymyxin or aminoglycoside-based regimens for infections due to drug-resistant P. aeruginosa. Multivariate logistic regression was performed controlling for factors associated with treatment to assess the independent impact of ceftolozane/tazobactam on clinical cure, acute kidney injury (AKI), and in-hospital mortality.
Results
A total of 200 patients were included (100 in each treatment arm). The cohort …
学术搜索中的文章
JM Pogue, KS Kaye, MP Veve, TS Patel, AT Gerlach… - Clinical Infectious Diseases, 2020